FENC Key Statistics, Chart & Performance
The current stock price of FENC is 7.58 USD. In the past month the price decreased by -0.79%. In the past year, price increased by 28.26%.
FENC Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.72 | 396.12B | ||
| AMGN | AMGEN INC | 15.09 | 177.76B | ||
| GILD | GILEAD SCIENCES INC | 14.73 | 149.71B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 27.06 | 119.17B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.8 | 84.19B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 783.14 | 52.76B | ||
| INSM | INSMED INC | N/A | 36.31B | ||
| NTRA | NATERA INC | N/A | 33.06B | ||
| BIIB | BIOGEN INC | 11.11 | 27.29B | ||
| INCY | INCYTE CORP | 16.5 | 20.79B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.6 | 21.14B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 20.76B |
Related stock screener links
About FENC
Company Profile
Fennec Pharmaceuticals, Inc. is a specialty pharmaceutical company. The company is headquartered in Research Triangle Park, North Carolina. The company went IPO on 2001-06-05. The company sells its product through a field force, including Regional Pediatric Oncology Specialists and medical science liaisons who are helping to educate the medical communities and patients about cisplatin induced ototoxicity and its programs supporting patient access to PEDMARK. PEDMARK is an approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic, solid tumors. The company is a formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients. PEDMARK is a therapeutic agent with a dosing paradigm, across two open-label, randomized Phase III clinical studies, the Clinical Oncology Group (COG) Protocol ACCL0431 and SIOPEL 6. The company has established Fennec HEARS, a single source program designed to connect PEDMARK patients.
Company Info
FENNEC PHARMACEUTICALS INC
PO Box 13628, 68 Tw Alexander Dr
RESEARCH TRIANGLE PARK NORTH CAROLINA 27709 US
CEO: Rostislav Raykov
Employees: 36
Phone: 19196364530
FENNEC PHARMACEUTICALS INC / FENC FAQ
What does FENC do?
Fennec Pharmaceuticals, Inc. is a specialty pharmaceutical company. The company is headquartered in Research Triangle Park, North Carolina. The company went IPO on 2001-06-05. The company sells its product through a field force, including Regional Pediatric Oncology Specialists and medical science liaisons who are helping to educate the medical communities and patients about cisplatin induced ototoxicity and its programs supporting patient access to PEDMARK. PEDMARK is an approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic, solid tumors. The company is a formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients. PEDMARK is a therapeutic agent with a dosing paradigm, across two open-label, randomized Phase III clinical studies, the Clinical Oncology Group (COG) Protocol ACCL0431 and SIOPEL 6. The company has established Fennec HEARS, a single source program designed to connect PEDMARK patients.
Can you provide the latest stock price for FENNEC PHARMACEUTICALS INC?
The current stock price of FENC is 7.58 USD. The price decreased by -0.26% in the last trading session.
Does FENC stock pay dividends?
FENC does not pay a dividend.
What is the ChartMill technical and fundamental rating of FENC stock?
FENC has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Which stock exchange lists FENC stock?
FENC stock is listed on the Nasdaq exchange.
What is the market capitalization of FENC stock?
FENNEC PHARMACEUTICALS INC (FENC) has a market capitalization of 258.86M USD. This makes FENC a Micro Cap stock.
FENC Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to FENC. When comparing the yearly performance of all stocks, FENC turns out to be only a medium performer in the overall market: it outperformed 58.45% of all stocks.
FENC Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to FENC. FENC may be in some trouble as it scores bad on both profitability and health.
FENC Financial Highlights
Over the last trailing twelve months FENC reported a non-GAAP Earnings per Share(EPS) of -0.23. The EPS decreased by -475% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -14.09% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
FENC Forecast & Estimates
11 analysts have analysed FENC and the average price target is 14.79 USD. This implies a price increase of 95.12% is expected in the next year compared to the current price of 7.58.
For the next year, analysts expect an EPS growth of -227846112347928100% and a revenue growth -20.4% for FENC